Investigational drug · Phase 3
Surovatamig
Also called: AZD0486, TNB-486
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
10
Any phase or sponsor naming "Surovatamig"
First trial start
2023
Dec 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Surovatamig", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Non-Hodgkin Lymphoma
- Large B-cell Lymphoma
- Untreated Follicular Lymphoma
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Follicular Lymphoma (FL)
- Large B-Cell Lymphoma (LBCL)
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Mantle-cell Lymphoma
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Surovatamig" as an intervention, largest first.
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06549595 · 1,018 participants (planned) · Start Aug 7, 2024 · Primary completion Nov 26, 2031
Drug: Surovatamig; R-CHOP and 2 more · For: Untreated Follicular Lymphoma
Sites: Huntsville, Alabama; Anchorage, Alaska; Phoenix, Arizona · 244 sites in all
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07509151 · 420 participants (planned) · Start May 5, 2026 · Primary completion Aug 29, 2031
Drug: Surovatamig · For: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Sites: La Jolla, California; Denver, Colorado; New Haven, Connecticut · 44 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06564038 · 408 participants (planned) · Start Jan 30, 2025 · Primary completion May 20, 2030
Drug: Surovatamig; Prednisone (or equivalent) and 5 more · For: Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Mantle-cell Lymphoma and 2 more
Sites: Boston, Massachusetts; Hackensack, New Jersey; New Brunswick, New Jersey · 66 sites in all
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06526793 · 270 participants (planned) · Start Nov 27, 2024 · Primary completion Apr 21, 2028
Drug: Surovatamig · For: B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL); Large B-Cell Lymphoma (LBCL)
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 94 sites in all
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06137118 · 255 participants (planned) · Start Dec 29, 2023 · Primary completion Jan 6, 2028
Drug: Surovatamig · For: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 83 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07123454 · 164 participants (planned) · Start Sep 24, 2025 · Primary completion Jul 4, 2028
Drug: AZD4512; Surovatamig · For: B-cell Non-Hodgkin Lymphoma
Sites: Irvine, California; Jacksonville, Florida; Rochester, Minnesota · 23 sites in all
- A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular LymphomaPivotal-lookingNot yet recruiting
Australasian Leukaemia and Lymphoma GroupAcademic, hospital or other
NCT07736950 · 140 participants (planned) · Start Jan 12, 2027 · Primary completion Jan 13, 2035
Drug: Surovatamig · For: Follicular Lymphoma
- Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07201558 · 48 participants (planned) · Start Dec 2, 2025 · Primary completion Jun 27, 2028
Drug: Surovatamig · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Fullerton, California; Plantation, Florida · 35 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07571746 · 43 participants (planned) · Start Mar 28, 2026 · Primary completion Oct 13, 2028
Drug: Surovatamig · For: Primary Membranous Nephropathy
Sites: Los Angeles, California; Iowa City, Iowa; Bethesda, Maryland · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- T-cell engaging antibodies for B-cell lymphomas.
Kim DH, Kim TM · Semin Hematol 2025
- The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma.
Hambleton H, Cheah CY · Expert Opin Investig Drugs 2025
- TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK, Prabhakar K, Ugamraj HS, et al. · MAbs 2021
Also in development for B-cell Non-Hodgkin Lymphoma
- AZD4512Phase 21 trial
AstraZeneca · B-cell Non-Hodgkin Lymphoma
- DS3790aPhase 21 trial
Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- HP-002Phase 21 trial
Shanghai Helioson Pharmaceutical Co., Ltd. · B-Cell Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.